India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Indian biotechnology firm Biocon has reinforced its ambitions to bring to market an orally delivered insulin and said it stays firmly on track as it found several "unique and positive" takeaways from its recently concluded Phase III clinical trials in India
You may also be interested in...
BMS, Biocon Team Up To Rekindle Oral Insulin Hopes
After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”
BMS, Biocon Team Up To Rekindle Oral Insulin Hopes
After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”
Biocon Completes Phase I Trial For Lantus Biosimilar, As Speculation Builds On Deal For Oral Insulin
A steadily developing pipeline – including a biosimilar of Sanofi’s blockbuster diabetes therapy Lantus – is starting to bear fruit. Meanwhile, speculation is building that Biocon is close to partnering its oral insulin IN-105, with Bristol-Myers Squibb as a rumored suitor.